CN EN
news
BioDuro-Sundia Receives 2021 Best Partner Award from Haihe Biopharma Drug Discovery Department
Shanghai, January 6, 2022 – BioDuro-Sundia won the “Best Partner Award in Chemistry & Biology 2021” issued by Haihe Biopharma Drug Discovery Department, in recognition of the great contribution by our drug discovery team in 2021. Dr. Bing Yu, Senior Director of Drug Discovery Biology, and Dr. Wangyang Tu, Senior Director of Medicinal Chemistry, visited our Zhangjiang R&D Center, and shared the joy together with the Drug R&D team of BioDuro-Sundia. Dr. Jiong Chen, Vice President of Shanghai Zhangjiang Chemistry R&D Department, Dr. Teng Lin, Senior Director of Drug Discovery Biology and Mr. Zhenhan Lei, Senior Commercial Director, received the award and presented the project summary.
January 06, 2022
BioDuro-Sundia Acquires 2nd US-based Commercial Drug Product Manufacturing Facility along with Commercial Supply Agreement
SAN DIEGO, November 08, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a commercial supply agreement. Subject to customary closing conditions, BioDuro-Sundia will assume operations on January 1, 2022.
November 08, 2021
Congratulations to Immunophage Biotech on the US FDA Approval to Initiate Clinical Trials for their Small Molecule MIF Inhibitor IPG1094
SHANGHAI, August 27, 2021 – Congratulations to our partner, Nanjing Immunophage Biotech, for receiving Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to in
August 27, 2021
BioDuro-Sundia Acquires US-based Phase III/Commercial Drug Product Manufacturing Facility
SAN DIEGO, August 23, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a 40,000 ft2 commercial oral solid dose manufacturing facility located at 72 Fairbanks, Irvine, CA, USA. Subject to customary closing conditions, BioDuro-Sundia expects to begin commercial service operations at the site on January 1, 2022.
August 23, 2021
BioDuro-Sundia Strengthens Leadership with New CFO and Operations SVP
SAN DIEGO and SHANGHAI, June 29, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of two senior leadership positions: Nee Chuan Teo as Chief Financial Officer and Alice Lv, PhD as Senior Vice President of Operations. Both directly report to the global CEO. “The appointmen
June 29, 2021
Total 83 12345678...1617
Large Molecule Bioanalysis Services
BioDuro-Sundia’s large molecule bioanalysis DMPK/ADME platform provides representative research services to a variety of molecular modalities including mAbs, ADC, oligonucleotides, large or small molecule biomarkers or metabolites, proteins and peptides.
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all